MAPT and Cognitive impairment: We, therefore, sought to evaluate MRI-free tau PET pipelines specifically in the context of clinically unimpaired (CU) individuals, where it is expected that tau PET values will have a more restricted range and biologically relevant elevations will be more subtle than what is observed among individuals with clinical impairment (mild cognitive impairment and dementia).